Kalytera Announces Data from Study in Rats Demonstrating Proof of Concept for R-107 in COVID-19 Associated PAH
SAN FRANCISCO, June 09, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new proof-of-concept data for R-107, its liquid nitric oxide donor, in …